SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Company: Sprouts Farmers Market, Inc. (NASDAQ: SFM) is a specialty grocery store chain that operates in the U.S. What is the class period? June 4, 2025 - October 29, 2025. What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Sprouts Farmers Market, Inc. during the class period because the Company allegedly misled investors regarding its growth potential. For more inf ...

Core Viewpoint - A class action lawsuit has been filed against Blue Owl Capital Inc. for allegedly misleading investors about its business prospects during a specified period [1][2]. Group 1: Allegations and Issues - The lawsuit claims that Blue Owl failed to disclose significant pressures on its asset base due to Business Development Company (BDC) redemptions [2]. - It is alleged that the company faced undisclosed liquidity issues as a result of these pressures [2]. - The complaint states that Blue Owl was likely to limit or halt redemptions of certain BDCs, which was not communicated to investors [2]. - Positive statements made by the company regarding its business operations and prospects were deemed materially misleading [2]. Group 2: Legal Proceedings - Shareholders who purchased Blue Owl securities between February 6, 2025, and November 16, 2025, may be eligible to participate in the class action [1][3]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff, representing the interests of other class members [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Group 3: Company Background - Blue Owl Capital Inc. is an asset management firm that specializes in alternative investment solutions, primarily in private credit [1]. - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance [4].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a class action lawsuit due to allegations of misleading investors regarding its prostate cancer therapeutic candidates and supply chain quality [1][2]. Group 1: Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [1]. - The lawsuit was filed on behalf of investors who purchased or acquired Telix securities during the class period [1]. Group 3: Allegations - The complaint alleges that during the class period, defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates, TLX591 and TLX592, as well as the quality of its supply chain and partners [2]. - Investors were reportedly surprised on July 22, 2025, when Telix disclosed an SEC investigation into its disclosures regarding the development of its prostate cancer therapeutic candidates [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data for the drug product used in the phase 3 clinical trial [3]. Group 4: Impact on Stock - Following the announcement of the SEC investigation and the CRL from the FDA, the price of Telix's American Depositary Shares (ADSs) declined [3].

Core Viewpoint - Freeport-McMoran Inc. is facing a class action lawsuit due to allegations of misleading investors about safety conditions at its mines, particularly the Grasberg Block Cave mine in Indonesia, which has resulted in worker fatalities and stock price declines [1]. Group 1: Company Overview - Company: Freeport-McMoran Inc. (NYSE: FCX) is a mining company [1]. - Class period for the lawsuit is from February 15, 2022, to September 24, 2025 [1]. Group 2: Allegations - The lawsuit claims that Freeport failed to disclose inadequate safety measures at the Grasberg Block Cave mine, which posed a heightened risk of worker fatalities [1]. - The complaint states that the lack of safety precautions led to regulatory, litigation, and reputational risks that were not disclosed to investors [1]. - Following an incident on September 9, 2025, where seven workers could not evacuate safely, Freeport's stock price declined, and it fell further on September 24, 2025, after two workers were reported fatally injured [1]. Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must file their papers by January 12, 2026 [1]. - Participation in the class action is not required to be eligible for recovery, and shareholders can remain absent class members if they choose [1].

Core Insights - Class actions have been initiated for stockholders of James Hardie Industries plc and Baxter International, Inc. with specific deadlines for lead plaintiff petitions [1] James Hardie Industries plc (NYSE:JHX) - The class period for the James Hardie lawsuit is from May 20, 2025, to August 18, 2025 [6] - Allegations include that James Hardie's North America Fiber Cement segment faced weakening demand due to distributor inventory destocking, which the company was aware of by April and early May 2025 [6] - The company falsely represented that demand remained strong and inventory levels were "normal" [6] - On August 19, 2025, a 12% sales decline in the segment was revealed, attributed to "normalization of channel inventories," leading to a share price drop of over 34% [6] Baxter International, Inc. (NYSE:BAX) - The class period for the Baxter lawsuit is from February 23, 2022, to July 30, 2025 [6] - Allegations state that the Novum LVP suffered systemic defects causing malfunctions, which exposed patients to serious risks [6] - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects [6] - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [6] - There was a heightened risk that existing Novum LVPs would be taken out of service, and new sales would be paused, contradicting Baxter's statements about the product's safety and efficacy [6]

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a class action lawsuit due to allegations of misleading investors regarding its prostate cancer therapeutic candidates, TLX591 and TLX592, during the class period from February 21, 2025, to August 28, 2025 [1][2]. Summary by Sections Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1]. Class Action Details - A class action was filed on behalf of investors who purchased Telix securities during the specified class period, alleging that the company materially overstated the progress and quality of its prostate cancer therapeutic candidates and supply chain [1][2]. Allegations and Developments - The complaint states that on July 22, 2025, Telix disclosed an SEC investigation into its disclosures regarding the development of TLX591 and TLX592 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data for the drug product used in the phase 3 clinical trial [3]. - The CRL also indicated that notices of deficiency were issued to Telix's third-party manufacturing and supply chain partners, which must be addressed before resubmitting the Biologics License Application (BLA) [3]. Investor Actions - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by January 9, 2026 [4]. - Investors can remain absent class members if they choose not to participate in the case [4]. Legal Representation - Robbins LLP is leading the class action, emphasizing that all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against Sprouts Farmers Market, Inc. for allegedly misleading investors about its growth potential during fiscal year 2025 [1][2]. Allegations - The complaint claims that Sprouts' management provided overly optimistic information regarding the company's growth potential, suggesting resilience in its customer base despite macroeconomic pressures [2]. - It is alleged that the management concealed significant adverse facts, including the possibility of a slowdown in sales growth due to a more cautious consumer environment [2]. Financial Performance - On October 29, 2025, Sprouts reported disappointing third-quarter results, with comparable store growth falling below expectations [3]. - The company also issued a disappointing fourth-quarter guidance and reduced its full-year estimates, attributing these results to challenging year-on-year comparisons and signs of a softening consumer [3]. - Following the announcement, Sprouts' stock price plummeted from $104.55 to $77.25, marking a decline of approximately 26.11% [3].

Core Viewpoint - A class action has been filed against StubHub Holdings, Inc. for allegedly misleading investors regarding its IPO registration statement, particularly concerning free cash flow and vendor payment timing changes [1][2]. Financial Performance - StubHub reported a free cash flow of negative $4.6 million for Q3 2025, marking a 143% decrease from the positive $10.6 million reported in the same quarter the previous year [3]. - The company's net cash provided by operating activities was $3.8 million, a 69.3% decline from $12.4 million in the prior year [3]. Stock Performance - Following the release of disappointing financial results, StubHub's stock price dropped by $3.95 per share, or 20.9%, closing at $14.87 on November 14, 2025 [4]. - By the time the class action commenced, StubHub's stock had fallen to as low as $10.31 per share, representing a nearly 56% decline from the IPO price of $23.50 per share [4].

Core Points - A class action has been filed against Alexandria Real Estate Equities, Inc. (ARE) on behalf of investors who acquired its securities between January 27, 2025, and October 27, 2025 [1] - The allegations include misleading statements regarding Alexandria's financial prospects, particularly concerning revenue and funds from operations (FFO) growth for fiscal year 2025 [2] - On October 27, 2025, Alexandria reported disappointing third-quarter financial results and reduced its FFO guidance for the full year, citing lower occupancy rates and a significant real estate impairment charge of $323.9 million [3] Company Overview - Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) focused on life science real estate, including lab space and research facilities for tenants in the pharmaceutical, biotech, and agricultural technology sectors [1] - The company has been promoting its Long Island City (LIC) property as a key part of its Megacampus™ strategy, which has come under scrutiny due to recent allegations [2] Financial Performance - The company experienced a significant decline in stock price, dropping approximately 19% from $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025, following the announcement of its financial results [3]

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corporation, alleging that the company made false and misleading statements regarding its merger with Cedar Fair, L.P. and its financial health prior to the merger [1][3]. Summary by Sections Merger Details - The merger between Legacy Six Flags and Cedar Fair closed on July 1, 2024, after receiving shareholder approval on March 12, 2024. The merged entity was renamed CopperSteel HoldCo, Inc., which later changed its name to Six Flags and began trading under the ticker symbol "FUN" on the NYSE [1][3]. Allegations - The lawsuit claims that Legacy Six Flags had significantly underinvested in its parks and operations, neglecting essential maintenance and improvements for several years before the merger [3]. - It is alleged that Legacy Six Flags required millions of dollars in undisclosed capital and operational expenditures to maintain or grow its market share in the competitive amusement park industry [3]. - The complaint states that the financial projections presented to investors were unrealistic and not based on the actual conditions of the company at the time of the merger, due to the undisclosed capital needs and chronic disinvestment [3]. Stock Performance - On the merger closing date, Six Flags stock was trading above $55 per share. However, the stock price subsequently plummeted to as low as $20 per share, representing a nearly 64% decline [4].